A number of investment brokers have recently updated their price targets on shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/29/2016 – SunTrust began new coverage on Agios Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 57 price target on the stock.

03/04/2016 – Agios Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 50 price target on the stock.

03/01/2016 – Janney Montgomery Scott began new coverage on Agios Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 43 price target on the stock.

02/19/2016 – Agios Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 56 price target on the stock.

01/21/2016 – Credit Suisse began new coverage on Agios Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 75 price target on the stock.

11/09/2015 – Agios Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Roth Capital. They now have a USD 75 price target on the stock.

11/09/2015 – Agios Pharmaceuticals, Inc. had its “perform” rating reiterated by analysts at Oppenheimer.

07/22/2015 – Northland Securities began new coverage on Agios Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 135 price target on the stock.

06/16/2015 – Agios Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Desjardins.

06/02/2015 – Citigroup began new coverage on Agios Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 132 price target on the stock.

05/08/2015 – MLV & Co began new coverage on Agios Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 130 price target on the stock.

05/03/2015 – Agios Pharmaceuticals, Inc. was upgraded to “hold” by analysts at Zacks.

12/09/2014 – Agios Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen.

12/02/2014 – Agios Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 90 price target on the stock.

11/07/2014 – Agios Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Goldman Sachs. They now have a USD 76 price target on the stock.

The share price of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was up +1.00% during the last day of trading, with a day high of 44.37. 663685 shares were traded during the last session.

The stock’s 50 day moving average is 45.43 and its 200 day moving average is 51.58. The stock’s market capitalization is 1.64B. Agios Pharmaceuticals, Inc. has a 52-week low of 33.50 and a 52-week high of 126.35.

View other investors thoughts on Agios Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.